Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.62 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.61 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.58 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20623014 | 0.89 | TBXAS1 (0.62) | CYP19A1CYP11B1CYP11B2TBXAS1CYP2A6 | |
| SCHEMBL22063899 | 0.88 | CYP19A1 (0.57) | CYP19A1CYP11B1CYP11B2TBXAS1CYP1A2 | |
| SCHEMBL20601870 | 0.87 | CYP19A1 (0.66) | CYP19A1CYP11B1CYP11B2TBXAS1CYP2A6 | |
| SCHEMBL22064348 | 0.82 | CYP19A1 (0.60) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL23643821 | 0.82 | TBXAS1 (0.55) | CYP19A1CYP11B1CYP11B2TBXAS1CYP1A2 | |
| SCHEMBL1024261 | 0.81 | CYP11B1 (0.84) | CYP19A1CYP11B1CYP11B2TBXAS1CYP2A6 | |
| SCHEMBL23643573 | 0.81 | CYP19A1 (0.44) | CYP19A1CYP11B1CYP11B2TBXAS1CYP1A2 | |
| SCHEMBL6323414 | 0.80 | CYP19A1 (0.79) | CYP19A1CYP11B1CYP11B2TBXAS1CYP2A6 | |
| Hydrochloric Acid SCHEMBL1775141 | 0.79 | CYP11B1 (0.81) | CYP19A1CYP11B1CYP11B2TBXAS1CYP2A6 | |
| SCHEMBL20602252 | 0.79 | TBXAS1 (0.58) | CYP19A1CYP11B1CYP11B2TBXAS1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3621955-B1 | DEGRADABLE IMIDAZOLIUM OLIGOMER AND POLYMER FOR ANTIMICROBIAL APPLICATIONS | AGENCY SCIENCE TECH & RES (SG) | 2021-07-14 | — | — | EP | disclosed |
| EP-3621955-B1 | DEGRADABLE IMIDAZOLIUM OLIGOMER AND POLYMER FOR ANTIMICROBIAL APPLICATIONS | AGENCY SCIENCE TECH & RES (SG) | 2021-07-14 | — | — | EP | disclosed |
| US-10927100-B2 | Degradable imidazolium oligomer and polymer for antimicrobial applications | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-02-23 | — | — | US | disclosed |
| US-10927100-B2 | Degradable imidazolium oligomer and polymer for antimicrobial applications | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2021-02-23 | — | — | US | disclosed |
| US-20200181122-A1 | Degradable Imidazolium Oligomer and Polymer for Antimicrobial Applications | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-06-11 | — | — | US | disclosed |
| US-20200181122-A1 | Degradable Imidazolium Oligomer and Polymer for Antimicrobial Applications | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-06-11 | — | — | US | disclosed |
| EP-3621955-A1 | DEGRADABLE IMIDAZOLIUM OLIGOMER AND POLYMER FOR ANTIMICROBIAL APPLICATIONS | Agency for Science, Technology and Research (SG) | 2020-03-18 | — | — | EP | disclosed |
| WO-2019004940-A1 | DEGRADABLE IMIDAZOLIUM OLIGOMER AND POLYMER FOR ANTIMICROBIAL APPLICATIONS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927100-B2 | Degradable imidazolium oligomer and polymer for antimicrobial applications | NOD2, CFTR, PUF60 | CYP19A1 4646/4885CYP11B1 3790/4885CYP11B2 3749/4885 |
| US-20200181122-A1 | Degradable Imidazolium Oligomer and Polymer for Antimicrobial Applications | NOD2, CFTR, PUF60 | CYP19A1 4646/4885CYP11B1 3790/4885CYP11B2 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.